Bifonazole 1% gel in the treatment of superficial dermatophytoses and erythrasma of the feet and groin.
An open, non-comparative study was carried out by four general practitioners into the efficacy and tolerability of a new antifungal preparation, bifonazole 1% gel. The preparation was used once daily to treat clinically diagnosed, superficial dermatophytoses and erythrasma of the feet or groin in 91 patients of which 51 were confirmed by mycological examination. A complete mycological evaluation was available for 28 patients and a cure was recorded in 23 (89%) of these cases. Four patients reported discomfort and burning on application of the preparation and changed to alternative treatments.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003354:Corynebacterium Infections / Q000188:drug therapy*; D003881:Dermatomycoses / Q000188:drug therapy*; D004894:Erythrasma / Q000188:drug therapy*; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy*; D005782:Gels; D006119:Groin; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014005:Tinea / Q000188:drug therapy
D000935:Antifungal Agents; D005782:Gels; D007093:Imidazoles; C036596:bifonazole